Zimmer and Orthofix suffer weak hip and knees; dj's regen unit carries on strongly
This article was originally published in Clinica
Executive Summary
Cost controls helped to bolster weaker-than-expected sales for Zimmer in the third quarter. While total sales reached $762.5m, a disappointing 9% increase from the same period last year, reduced general administrative and research and development expenses made up for the revenue shortfall and drove net earnings up to $168.6m or $0.70 per share, $0.03 better than analysts' consensus.